ACC 2025 Resource Hub  – 

Welcome to our resource hub for ACC 2025! This is a one-stop-shop for all your ACC needs. The conference will feature 300+ educational and late-breaking clinical research sessions and seven guideline-specific sessions across 11 learning pathways. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

  1. Conference Website
  2. Conference Registration
  3. Day-by-Day Conference Preview
  4. Conference Schedule; Online Program Planner

Day-of Conference Reports

1. Day #1 Highlights 

2. Day #2 Highlights 

Diabetes Therapy Highlights

  1. Full results of SOUL trial: Dr. Darren McGuire presents the superiority of oral semaglutide in cardiovascular events
  2. Retrospective analysis shows Lilly’s tirzepatide (Mounjaro) improves cardiovascular outcomes substantially in people with T2D and HFrEF
  3. GLP-1 RAs in heart failure: Is it all about weight loss?
  4. Meta-analysis suggests empagliflozin and dapagliflozin have comparable cardiovascular efficacy in patients with T2D
  5. Full results of STRIDE trial: Semaglutide improves maximum walking distance by 13% (+40 meters) and adverse clinical outcomes by 54% in people with T2D and peripheral artery disease
  6. Diagnosis, treatment, and clinical considerations of HFpEF: Sarcopenia as a potential risk of GLP-1 RA use in older patients
  7. Lipid management through risk assessment, prevention, and therapies
  8. Dr. Steven Nissen presents full results of phase 2 ALPACA trial: siRNA lepodisiran reduces Lp(a) by 94% at six months
  9. “The cardiometabolic jackpot”: Evidence-based dietary strategies and pharmacotherapies for durable weight loss
  10. Comprehensive overview of key updates, clinical evidence, and clinical pearls of GLP-1 RAs in obesity
  11. Systematic meta-analysis suggests SGLT-2 inhibitors may reduce atrial fibrillation risk in people with T2D compared to GLP-1 RAs
  12. Cardiovascular risk management in people with cardio-kidney-metabolic syndrome: GLP-1 RAs, SGLT-2 inhibitors, and finerenone
  13. The efficacy of GLP-1 RAs in women: Sex-based risk factors and key considerations
  14. Universal screening? Lively debates on coronary artery calcium scan and Lp(a) testing for CV risk stratification

Diabetes Big Picture Highlights

  1. “The threshold where history and opportunity converge”: ACC President Dr. Cathleen Biga on the role of innovation, quality, and equity in transformative care
  2. Preview of the Exhibit Hall: More than 280 booths offering insights on therapies and technologies for heart health

Previous ACC Coverage on CCKB

  1. ACC 2024 Full Report
  2. ACC 2023 Full Report
  3. ACC 2022 Full Report
  4. ACC 2021 Full Report
  5. ACC 2020 Full Report
  6. ACC 2019 Full Report
  7. ACC 2018 Full Report
  8. ACC 2017 Full Report
  9. ACC 2016 Full Report
ACC 2025 Resource Hub -
Top